No, because before then there will be action on potential approval for thyroid cancer, and we will find also find out if the improvements on bone scans are for real or not. Maybe Europe will be more amenable as well.
What's hard for them is that prostate is a rapidly evolving field with abiraterone becoming standard of care and for bone mets the new alpharadin looking very good.
Market Data 
Markets 
AI
